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We describe a case of a breastfeeding woman with an accidental warfarin overdose resulting in a 
markedly elevated prothrombin time. The breast-fed infant was evaluated and tested for ill effects. 
We discuss the use of warfarin while breast-feeding. [West J Emerg Med. 2011;12(2):216-217.]
We report a case of an accidental warfarin overdose in a 
breastfeeding 40-year-old woman. The patient had been 
prescribed warfarin at a dose of five milligrams per day to 
treat a pulmonary embolus that was diagnosed shortly after 
she underwent a caesarian section delivery. At the time of 
presentation, the patient had been taking warfarin for nearly 
two months. She had originally been given one-milligram 
tablets and instructed to take five tablets daily. However, one 
week prior to presentation, her refill prescription was 
dispensed as five-milligram tablets. Unaware of the change, 
the patient continued taking five tablets per day, for a total 
dose of 25 milligrams daily for seven days. The error was 
realized when she returned to the pharmacy requesting a refill 
after only one week, having completely run out of the 
medication.
Upon presentation, the patient was asymptomatic. 
Laboratory coagulation profile studies were markedly 
abnormal, with an international normalized ratio (INR) of 
greater than 10.0 (reference range 2.0-3.0 for standard 
anticoagulation, 2.5-3.5 for mechanical valve anticoagulation), 
a prothrombin time (PT) of greater than 100.0 seconds (normal 
range 9.3-11.2), and an activated partial thromboplastin time 
(aPTT) of 65.2 seconds (normal range 25.0-32.7). The previous 
INR, checked two weeks prior, was 2.3. Her complete blood 
count showed no anemia; in fact, the hematocrit was slightly 
higher than the last measured value two months prior. The 
patient was treated with a single five-milligram dose of oral 
vitamin K. Her warfarin was withheld for two days, after 
which the INR had decreased to 1.5 (subtherapeutic range).
Warfarin in therapeutic doses is generally considered safe 
in breastfeeding. Little information has been published on 
warfarin overdose during breastfeeding, whether in an acute 
setting (a single ingestion), or a prolonged exposure such as 
this one. We were concerned about the potential effects of the 
overdose on the patient’s breast-fed infant. The patient had 
been breastfeeding during the week of warfarin overdose, up 
until a few hours before presentation. Since birth, the baby had 
been fed almost solely breast milk.
The patient’s eight-week-old infant was brought in to the 
emergency department for evaluation and coagulation studies. 
History and examination revealed a healthy-appearing infant, 
with no signs or symptoms of bleeding. Coagulation studies 
revealed an INR of 1.0, PT of 10.3 seconds, and aPTT of 33.8 
seconds. The aPTT was slightly high compared to the 
laboratory upper limit of 32.4 seconds. However, coagulation 
studies performed on the infant three weeks prior to the 
overdose revealed that the aPTT was 38.9 seconds, also 
slightly elevated above the laboratory reference range (PT and 
INR were within normal limits at that time). One week before 
the infant’s first aPTT, the mother’s INR was 3.3, and five 
days later it was 2.3. Given that warfarin is considered very 
safe at standard doses during breast-feeding,1 it is unlikely that 
the infant’s previously elevated aPTT was related to the 
mother’s warfarin use.
Warfarin is known to pass the placental barrier during 
pregnancy and to cause birth defects as well as fetal and 
maternal coagulopathy. Fetal warfarin syndrome is 
characterized by skeletal abnormalities, including stippling of 
bones, nasal hypoplasia, and other abnormalities. However, 
warfarin is considered safe in lactation as it does not pass into 
breast milk to any measurable degree.2,3 This is due to several 
of its molecular properties: warfarin is ionic, making it a polar 
molecule and thus nonlipophilic.4 Less lipophilic compounds 
are unlikely to be excreted in breast milk. Additionally, 
warfarin is 99% bound to serum proteins, also associated with 
minimal transfer to breast milk. 5
While few human studies exist, the results of a 1977 case 
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in 13 lactating women. 6 The second part of the study 
evaluated seven breastfeeding infants whose mothers were 
taking therapeutic levels of warfarin. None of the seven 
infants had any change in plasma PT.
A MEDLINE search did not identify any case reports 
of a breastfeeding mother with a critically supratherapeutic 
INR. The pharmacokinetics of warfarin and prior case series 
indicate that warfarin is clinically undetectable in breast milk 
when the mother is taking standard doses. This case further 
suggests that warfarin, even in high doses resulting in a 
critically elevated maternal INR, does not cause a significant 
effect on the coagulation cascade or clinical bleeding in the 
breastfeeding infant.
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